Literature DB >> 32139236

Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Guidelines. 2020 Update.

Rosario Menéndez1, Catia Cilloniz2, Pedro Pablo España3, Jordi Almirall4, Ane Uranga3, Raúl Méndez5, David Rigau6, Antoni Torres7.   

Abstract

The guidelines for community-acquired pneumonia, last published in 2010, have been updated to provide recommendations based on a critical summary of the latest literature to help health professionals make the best decisions in the care of immunocompetent adult patients. The methodology was based on 6 PICO questions (on etiological studies, assessment of severity and decision to hospitalize, antibiotic treatment and duration, and pneumococcal conjugate vaccination), agreed by consensus among a working group of pulmonologists and an expert in documentation science and methodology. A comprehensive review of the literature was performed for each PICO question, and these were evaluated in in-person meetings. The American Thoracic Society guidelines were published during the preparation of this paper, so the recommendations of this association were also evaluated. We concluded that the etiological source of the infection should be investigated in hospitalized patients who have suspected resistance or who fail to respond to treatment. Prognostic scales, such as PSI, CURB 65, and CRB65, are useful for assessing severity and the decision to hospitalize. Different antibiotic regimens are indicated, depending on the treatment setting - outpatient, hospital, or intensive care unit - and the resistance of PES microorganisms should be calculated. The minimum duration of antibiotic treatment should be 5 days, based on criteria of clinical stability. Finally, we reviewed the indication of the 13-valent conjugate vaccine in immunocompetent patients with risk factors and comorbidity.
Copyright © 2020 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Keywords:  Antibiotic; Antibiótico; Microorganismos; Microorganisms; Neumonía; Pneumococcal vaccine; Pneumonia; Resistance; Resistente; Vacuna antineumocócica

Mesh:

Substances:

Year:  2020        PMID: 32139236     DOI: 10.1016/j.arbres.2020.01.014

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  2 in total

Review 1.  [Current microbiological aspects of community respiratory infection beyond COVID-19].

Authors:  R Cantón
Journal:  Rev Esp Quimioter       Date:  2021-03-22       Impact factor: 1.553

2.  CAPPRIC Study-Characterization of Community-Acquired Pneumonia in Spanish Adults Managed in Primary Care Settings.

Authors:  Jesús Molina; Amelia González-Gamarra; Leovigildo Ginel; Mª Encarnación Peláez; Juan Luis Juez; Antonio Artuñedo; Gonzalo Aldana; Enriqueta Quesada; Joan Josep Cabré; Antonio Gómez; Manuel Linares; Maria Teresa Marín; Pilar Yolanda Sanchez; Leonor Núñez; Jaime Gonzálvez; Enrique Mascarós; Javier López; Agustina Cano; José Herrero; María Carmen Serra; Enrique Cimas; Marta Pedrol; Juan Vicente Alfaro; Federico Martinón-Torres; Isabel Cifuentes; Cristina Méndez; Daniel Ocaña
Journal:  Microorganisms       Date:  2021-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.